161 related articles for article (PubMed ID: 23429710)
1. Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate.
Hapgood JP
Endocrinology; 2013 Mar; 154(3):985-8. PubMed ID: 23429710
[No Abstract] [Full Text] [Related]
2. Anaphylaxis from medroxyprogesterone acetate.
Selo-Ojeme DO; Tillisi A; Welch CC
Obstet Gynecol; 2004 May; 103(5 Pt 2):1045-6. PubMed ID: 15121602
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous depo-medroxyprogesterone acetate.
Cameron S
J Fam Plann Reprod Health Care; 2013 Apr; 39(2):75-7. PubMed ID: 23493590
[No Abstract] [Full Text] [Related]
4. Injectable contraception.
Mishell DR
J Reprod Med; 2002 Sep; 47(9 Suppl):777-9. PubMed ID: 12380405
[No Abstract] [Full Text] [Related]
5. New aspects of injectable contraception.
Phillips OP
Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
[TBL] [Abstract][Full Text] [Related]
6. Prospective clinical trials designed to assess the use of hormonal contraceptives and risk of HIV acquisition.
Morrison CS; Richardson BA; Celentano DD; Chipato T; Mmiro F; Mugerwa R; Padian NS; Rugpao S; Salata RA
J Acquir Immune Defic Syndr; 2005 Mar; 38 Suppl 1():S17-8. PubMed ID: 15867602
[No Abstract] [Full Text] [Related]
7. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with injectable progestogen- only contraceptives at University of Ilorin teaching hospital: a five year review.
Balogun OR; Raji HO
Niger Postgrad Med J; 2009 Dec; 16(4):260-3. PubMed ID: 20037621
[TBL] [Abstract][Full Text] [Related]
9. Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?
Polis CB; Achilles SL; Hel Z; Hapgood JP
Contraception; 2018 Mar; 97(3):191-197. PubMed ID: 29242082
[No Abstract] [Full Text] [Related]
10. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
Renner RM; Edelman AB; Kaunitz AM
Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
[No Abstract] [Full Text] [Related]
11. Injectable contraceptives: a worldwide perspective.
Affandi B
J Fam Plann Reprod Health Care; 2002 Jan; 28(1):3-4. PubMed ID: 16259804
[No Abstract] [Full Text] [Related]
12. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
[TBL] [Abstract][Full Text] [Related]
13. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use.
Atrio J
J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405
[No Abstract] [Full Text] [Related]
14. Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.
Huijbregts RP; Helton ES; Michel KG; Sabbaj S; Richter HE; Goepfert PA; Hel Z
Endocrinology; 2013 Mar; 154(3):1282-95. PubMed ID: 23354099
[TBL] [Abstract][Full Text] [Related]
15. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
16. Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.
Hapgood JP; Kaushic C; Hel Z
Endocr Rev; 2018 Feb; 39(1):36-78. PubMed ID: 29309550
[TBL] [Abstract][Full Text] [Related]
17. Lunelle monthly injectable contraceptive. An effective, safe, and convenient new birth control option.
Kaunitz AM
Arch Gynecol Obstet; 2001 Aug; 265(3):119-23. PubMed ID: 11561738
[TBL] [Abstract][Full Text] [Related]
18. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
19. Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women.
Weinberg A; Park JG; Bosch R; Cho A; Livingston E; Aweeka F; Cramer Y; Watts DH; Luque AE; Cohn SE
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):137-45. PubMed ID: 26413850
[TBL] [Abstract][Full Text] [Related]
20. Women's responses to Depo-Provera.
Freda MC; Abruzzo-Fogarassy M; Adams NV; Davini D; DeVore N; Merkatz IR
MCN Am J Matern Child Nurs; 1996; 21(4):183-6. PubMed ID: 8754434
[No Abstract] [Full Text] [Related]
[Next] [New Search]
